Last reviewed · How we verify
LNK01001
LNK01001 is an investigational therapeutic targeting immune checkpoint pathways to enhance anti-tumor immunity.
LNK01001 is an investigational therapeutic targeting immune checkpoint pathways to enhance anti-tumor immunity. Used for Cancer (specific indication under Phase 3 evaluation).
At a glance
| Generic name | LNK01001 |
|---|---|
| Sponsor | Lynk Pharmaceuticals Co., Ltd |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
While specific mechanistic details for LNK01001 are limited in public literature, it is being developed by Lynk Pharmaceuticals as an immunotherapy candidate in Phase 3 development. The drug likely modulates immune checkpoint signaling to reinvigorate T-cell mediated anti-tumor responses, though the precise molecular target requires confirmation from clinical trial data.
Approved indications
- Cancer (specific indication under Phase 3 evaluation)
Common side effects
Key clinical trials
- A Study of LNK01001 Capsule in Subjects With Active Rheumatoid Arthritis (COURAGE-RA) (PHASE3)
- A Study to Evaluate Efficacy and Safety of LNK01001 in Adults With Ankylosing Spondylitis (PHASE3)
- A Phase 3 Study of LNK01001 Capsule in Subjects With Moderate to Severe Atopic Dermatitis. (PHASE3)
- A Study of LNK01001 Capsule in Patients With Ankylosing Spondylitis (PHASE2)
- A Study of LNK01001 Capsule in Patients With Moderate to Severe Atopic Dermatitis (PHASE2)
- A Study of LNK01001 Capsule in Moderately to Severely Active Rheumatoid Arthritis (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LNK01001 CI brief — competitive landscape report
- LNK01001 updates RSS · CI watch RSS
- Lynk Pharmaceuticals Co., Ltd portfolio CI